Ab&B Bio-Tech CO., LTD. JS

江苏中慧元通生物科技股份有限公司

02627.HK

Develops, manufactures and commercializes vaccines in China, including a quadrivalent subunit influenza vaccine approved in 2023 and a freeze-dried human rabies vaccine candidate, with 11 other vaccine candidates in the pipeline.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Single product, business line or region
• Government or SOE customers and tenders
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Seasonality and cyclicality
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Investments and fair-value assets
• Related-party transactions and balances
• Chapter 18A biotech